Dhaka, BangladeshGMP & ISO Certified Manufacturer
Drug Discovery Division
Where molecules become medicines.
AI-augmented target identification, computational chemistry, and rational drug design — engineered for speed and precision.
Discovery by Numbers
Scale of our search
2.4B
Virtual compounds screened across our in-silico library in 2024.
340
Confirmed hits
62
Optimized leads
11
Development candidates
4.2 yrs
Avg. discovery-to-IND
Our discovery workflow
Six stages from unmet need to development-ready molecule.
01
Target ID
02
Hit Finding
03
Hit-to-Lead
04
Lead Opt
05
In-vivo PoC
06
Candidate Sel
AI & Computation
Generative chemistry, human-guided
Deep learning models propose novel scaffolds; medicinal chemists validate. Cuts lead-optimization cycles by ~40%.
Core capabilities
Target Biology
Genomics-driven target validation
In-silico Design
Structure-based & ligand-based
Med Chem
SAR, scaffold hopping, ADMET
Assay Dev
Biochemical & cell-based screens
Target class expertise
GPCRs
Kinases
Ion channels
Proteases
Nuclear receptors
PPIs
Technology backbone
Chemogenomics Cloud
5PB of curated bioactivity data
GPU Grid
384 A100s for molecular dynamics
High-throughput Screen
384-well robotic automation
Hit-to-lead funnel
Stage 1
2.4B
Virtual compounds
Stage 2
180K
Physical screen
Stage 3
340
Confirmed hits
Stage 4
62
Lead series
Stage 5
11
Candidates
Case Study
Program NVX-217: from target to IND in 3.1 years
3.1 yrs
Target to IND
$14M
Discovery cost
Best-in-class
PK profile
Discovery quality gates
Every candidate meets rigorous ADMET, safety, and developability criteria before nomination.
Selectivity ≥ 100x over off-targets
Oral bioavailability > 30%
hERG IC50 > 10 µM
Clean Ames & micronucleus
Predicted human dose < 200 mg/day
Academic & industry partners
MIT Broad
Scripps
EMBL
Crick Institute
Riken
IISc
Genentech
Schrödinger
Insilico
Recursion
Exscientia
Isomorphic
Bring your target to our platform
Discovery-as-a-service, milestone-based partnerships, and out-licensing opportunities.